Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 5Completed 5Unknown 3Active not recruiting 2Terminated 1Enrolling by invitation 1Available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 439Carboplatin 323Nivolumab 291Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 254Paclitaxel 249Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 169atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Radiosurgery 114Oxaliplatin 114Pemetrexed 113Etoposide 111Fluorouracil 110venetoclax 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × epigallocatechin gallate × Clear all
NCT05364008 2026-03-23

FRIEND

Yale University

Phase 3 Active not recruiting
33 enrolled

Leiomyoma

NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡